Market Research Logo

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2018

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2018, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 19, 1, 80, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Idiopathic Pulmonary Fibrosis - Overview
Idiopathic Pulmonary Fibrosis - Therapeutics Development
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmonary Fibrosis - Drug Profiles
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Amplia Therapeutics Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Corp, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by BerGenBio ASA, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by BreStem Therapeutics Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Co, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Celdara Medical LLC, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Certa Therapeutics Pty Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Galecto Biotech AB, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by KBP BioSciences Co Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by LifeMax Laboratories Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Medicenna Therapeutics Corp, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Miragen Therapeutics Inc, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Mission Therapeutics Ltd, H2 2018
Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix Inc, H2 2018
List of Figures
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report